Alternatively, since WRN helicase plays an essential role in MMR-deficient cells, treatment with a WRN inhibitor (Baltgalvis et al., 2024) might eliminate the emerging TMZ-resistant MMR-deficient glioblastoma cells. This evidence concerns the gene MRC1 and glioblastoma.